With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1187173-43-8,2,7-Diazaspiro[4.5]decan-1-one hydrochloride,as a common compound, the synthetic route is as follows.
1187173-43-8, 2,7-Diazaspiro[4.5]decan-1 -one hydrogen chloride (100 mg, 0.524 mmol) was dissolved in dichloromethane (5 mL) and triethylamine (0.146 mL, 1 .047 mmol). Then 3-[(trifluoromethyl)oxy]benzenesulfonyl chloride (0.098 mL, 0.577 mmol) was added and stirred for 16 h. The reaction mixture was concentrated in vacuo and the resulting residue was purified by MDAP to give 7-({3-[(trifluoromethyl)oxy]phenyl}- sulfonyl)-2,7-diazaspiro[4.5]decan-1 -one (85 mg, 0.222 mmol, 42% yield) as a white solid. 1 H NMR (400 MHz, DMSO-d6) delta ppm 1 .32 – 1 .48 (m, 2 H) 1.50 – 1 .64 (m, 1 H) 1 .65 – 1 .75 (m, 1 H) 1.89 – 1 .98 (m, 1 H) 1.99 – 2.09 (m, 1 H) 2.18 – 2.28 (m, 2 H) 3.19 (t, J=7.10 Hz, 2 H) 3.30 – 3.37 (m, 1 H) 3.65 (d, J=1 1 .62 Hz, 1 H) 7.69 (s, 1 H) 7.73 – 7.85 (m, 4 H). MS ES+ve m/z 379 (M+H).
As the paragraph descriping shows that 1187173-43-8 is playing an increasingly important role.
Reference：
Patent; CONVERGENCE PHARMACEUTICALS LIMITED; GLEAVE, Robert James; HACHISU, Shuji; PAGE, Lee William; BESWICK, Paul John; WO2011/141728; (2011); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem